New strategies for cancer immunotherapy: targeting regulatory T cells

Genome Medicine
Francesca Finotello, Zlatko Trajanoski


The immunosuppressive action of regulatory T (Treg) cells is one mechanism attributed to the limited success of cancer immunotherapies with checkpoint blockers. Two recent studies report distinct transcriptional profiles of tumor-infiltrating Treg cells and expression of specific molecules, suggesting novel strategies to overcome resistance to cancer immunotherapy.


Oct 23, 2018·Frontiers in Oncology·Francesca Finotello, Federica Eduati
Dec 12, 2018·NPJ Precision Oncology·Malak AbedalthagafiKara M Foshay
Mar 16, 2018·Cancer Immunology, Immunotherapy : CII·Francesca Finotello, Zlatko Trajanoski
Aug 15, 2018·The Journal of Clinical Investigation·Cameron McDonald-HymanBruce R Blazar
Dec 22, 2020·PLoS Neglected Tropical Diseases·Liaoxun LuLichen Zhang
Dec 17, 2019·International Immunopharmacology·Vida HashemiFarhad Jadidi-Niaragh
Feb 13, 2021·International Immunopharmacology·Mahdi Dehghan-ManshadiHoushang Rafatpanah
Dec 8, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Yun-Gyoo LeeIn Gyu Hwang

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.